Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Emgality ® ▼ (galcanezumab)
Emgality®▼ (galcanezumab) Pen: Dose Confirmation
The pre-filled pen has visual and audible signals to confirm the injection was successfully completed.
The Instructions for Use state the following:
After you press the teal injection button, you will hear 2 loud clicks.
Press and hold the teal injection button; you will hear a loud click
You will hear a second click in about 5 to 10 seconds after the first one.
This second click tells you that the injection is complete. 1
You will know the injection is complete when you can see the grey plunger at the top of the clear base. 1
What if more than 2 Clicks are heard during the Injection - 2 loud Clicks and a soft One. Is the Injection complete?
Some patients may hear a soft click right before the second loud click. That is normal operation of the pen. The pen should not be removed from the skin until the second loud click is heard.1
Patients with vision or hearing problems should not use the pen without help from a caregiver.1
The instructions for using the pen included with the Package Leaflet, must be followed carefully. The pre-filled pen is for total use only.2
After training, patients may self-inject galcanezumab if a healthcare professional determines that it is appropriate. 2
2. Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: March 18, 2019